Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Journal of Crohn s and Colitis|2021Cited by 34
DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT IIWalter Reinisch, Séverine Vermeire, Maria Kłopocka et al.|Journal of Crohn s and Colitis|2019Cited by 5
P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)Walter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Inflammatory Bowel Diseases|2019Cited by 4
DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitisWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Journal of Crohn s and Colitis|2019Cited by 2
Tu1737 – Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MADCAM-1) Antibody Shp647 in Ulcerative Colitis: Results from the Open-Label Extension Study Turandot IiWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Gastroenterology|2019Cited by 1